Anti-NTB-A antibodies and related compositions and methods

• US 10,435,468 B2
• Filed: 06/14/2017
• Issued: 10/08/2019
• Est. Priority Date: 12/21/2012
• Status: Active Grant

• Current Assignee: Seagen Inc.
• Original Assignee: Seattle Genetics Incorporated
• Inventors: Lewis, Timothy S., Law, Che-Leung
• Primary Examiner(s): Bristol, Lynn A
• Application Number:
  US15/622,411
• Publication Number:
  US 20170320944A1
• Time in Patent Office: 846 Days
• Field of Search: 4241331, 4241781
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 2317/20 characterized by taxonomic origin
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/64 comprising a combination of variable region and constant region components
• CPC Class Codes: C07K 2317/71 Decreased effector function due to an Fc-modification
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/77 Internalization into the cell
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.

Claims

1. An isolated polynucleotide comprising a sequence encoding a heavy chain variable region and a light chain variable region of an antibody that specifically binds to human NTB-A (SLAMF6), wherein the heavy chain variable region comprises:

a CDR-H1 amino acid sequence as shown in SEQ ID NO;

5 or SEQ ID NO;

11;

a CDR-H2 amino acid sequence as shown in SEQ ID NO;

6 or SEQ ID NO;

12;

a CDR-H3 amino acid sequence as shown in SEQ ID NO;

7 or SEQ ID NO;

13;

and wherein the light chain variable region comprises;

a CDR-L1 amino acid sequence as shown in SEQ ID NO;

8 or SEQ ID NO;

14;

a CDR-L2 amino acid sequence as shown in SEQ ID NO;

9 or SEQ ID NO;

15; and

a CDR-L3 amino acid sequence as shown in SEQ ID NO;

10 or SEQ ID NO;

16, respectively.

2. An isolated vector comprising the polynucleotide of claim 1.

3. An isolated host cell comprising the vector of claim 2.

4. A method of making an anti-NTB-A (SLAMF6) antibody or antigen binding fragment thereof, wherein the method comprises:

a) culturing the host cell of claim 3 under conditions suitable for expression of the polynucleotide encoding the antibody or antigen binding fragment thereof; and

b) isolating the antibody or antigen binding fragment thereof.

5. A method of making an anti-NTB-A (SLAMF6) antibody drug conjugate, wherein the method comprises:

a) culturing the host cell of claim 3 under conditions suitable for expression of the polynucleotide encoding the antibody or antigen binding fragment thereof;

b) isolating the antibody or antigen binding fragment thereof; and

c) conjugating a cytotoxic agent to the antibody or antigen binding fragment thereof.